Literature DB >> 26479761

A Multinational Survey on Actual Diagnostics and Treatment of Subacute Sclerosing Panencephalitis.

Martin Häusler1, Ayse Aksoy2, Michael Alber3, Sakir Altunbasak4, Aydan Angay5, Oana Tarta Arsene6, Dana Craiu6, Hans Hartmann7, Semra Hiz-Kurul8, Takashi Ichiyama9, Catrinel Iliescu6, Bosanka Jocic-Jakubi10, Rudolf Korinthenberg11, Gülsen Köse12, Marissa B Lukban13, Mehpare Ozkan2, Iliyana Patcheva14, Jens Teichler15, Mihaela Vintan16, Ahmet Yaramis17, Coskun Yarar18, Uluc Yis8, Deniz Yuksel2, Banu Anlar19.   

Abstract

Subacute sclerosing panencephalitis (SSPE) is a chronic infection of the central nervous system caused by the measles virus (MV). Its prevalence remains high in resource poor countries and is likely to increase in the Northern Europe as vaccination rates decrease. Clinical knowledge of this devastating condition, however, is limited. We therefore conducted this multinational survey summarizing experience obtained from more than 500 patients treated by 24 physicians in seven countries. SSPE should be considered in all patients presenting with otherwise unexplained acquired neurological symptoms. In most patients, the diagnosis will be established by the combination of typical clinical symptoms (characteristic repetitive myoclonic jerks), a strong intrathecal synthesis of antibodies to MV and typical electroencephalogram findings (Radermecker complexes). Whereas the therapeutic use of different antiviral (amantadine, ribavirin) and immunomodulatory drugs (isoprinosine, interferons) and of immunoglobulins has been reported repeatedly, optimum application regimen of these drugs has not been established. This is partly due to the absence of common diagnostic and clinical standards focusing on neurological and psychosocial aspects. Carbamazepine, levetiracetam, and clobazam are the drugs most frequently used to control myoclonic jerks. We have established a consensus on essential laboratory and clinical parameters that should facilitate collaborative studies. Those are urgently needed to improve outcome. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26479761     DOI: 10.1055/s-0035-1564618

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  3 in total

Review 1.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 2.  Trends and Treatment of Sub-Acute Sclerosing Panencephalitis: An Updated Review.

Authors:  Shahzeb Ali Memon; Syed Shabbir Afzal; Alaa Tukruna; Asma Tasnim Khan; Sameer Saleem Tebha; Zain Ali Zaidi
Journal:  Glob Pediatr Health       Date:  2021-12-21

Review 3.  Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas.

Authors:  Pauline Samia; Katherine Oyieke; Dorcas Tunje; Anaita Udwadia-Hegde; Kristen Feemster; Ibrahim Oncel; Banu Anlar
Journal:  Curr Treat Options Neurol       Date:  2022-03-19       Impact factor: 3.972

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.